Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PD182
- Development stage
- Unknown
- Modality
- Antibody-Based Therapeutics
01
Overview
PD182 is a polyclonal anti-idiotype antibody generated through rabbit immunization against adalimumab F(ab’)2. Developed using an advanced proteogenomics approach and strategic enrichment workflow, PD182 exhibits high specificity and affinity for adalimumab, with significantly reduced off-target binding to human IgG compared to commercially available anti-idiotypes. This makes it a promising tool for pharmacokinetic applications, capable of distinguishing between blocking (type 1) and non-blocking (type 2) variants.
Beyond the preview
Go deeper on PD182.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PD182.